Plasma Exchange in Acute and Acute on Chronic Liver Failure

Liver failure in the context of acute (ALF) and acute on chronic liver failure (ACLF) is associated with high mortality in the absence of a liver transplant. For decades, therapeutic plasma exchange (TPE) is performed for the management of immune-mediated diseases. TPE has emerged as an attractive extracorporeal blood purification technique in patients with ALF and ACLF. The basic premise of using TPE is to remove the toxic substances which would allow recovery of native liver functions by facilitating liver regeneration. In recent years, encouraging data have emerged, suggesting the benefits of TPE in patients with liver failure. TPE has emerged as an attractive liver support device for the failing liver until liver transplantation or clinical recovery. The data in patients with ALF suggest routine use of high-volume TPE, while the data for such a strategy are less robust for patients with ACLF.

Automated summary

Therapeutic plasma exchange (TPE) has emerged as an attractive extracorporeal blood purification technique in patients with acute liver failure (ALF) and acute on chronic liver failure (ACLF), showing benefits by promoting liver regeneration through the removal of toxic substances. TPE may serve as a liver support device for patients with failing liver until liver transplantation or clinical recovery, with routine high-volume TPE recommended for ALF patients but less robust data for ACLF patients.